Cyclavance®
Adaptable Relief for Atopic Dogs and Cats. Manage the long-term cause with Cyclavance®
Cyclavance® is a potent 100mg/ml ciclosporin solution, equally as effective as capsules.
Product features & benefits:
- 4 presentations - all pack sizes can be used with different weights of dog or cat depending on treatment frequency
- 2 sizes of syringe - accurate to the nearest kg for any size dog or cat
- Broached bottles last a full 6 months thanks to the Adaptor Cap design
- Once clinical signs are satisfactorily controlled, treatment can be reduced to every other day or twice weekly
- As a liquid, Cyclavance® allows accurate dosing to the nearest kg in one easy administration – limiting the risks and inefficiencies of under and overdosing
- Adaptor Cap - Includes valve for easy, safe storage and a broached shelf life of 6 months
- Luer Lock - Syringe and Adaptor Cap mean no leaks or lost product
- 100mg/ml - Small volume for ease of administration
- Ciclosporin has over 10 years of safety data to support its use in atopic dogs.
Presentations available:
- 5ml
- 15ml
- 30ml
- 50ml
Use medicines responsibly. www.noah.co.uk/responsible.
Further information is available on the SPC or on request from Virbac Ltd.
Product FAQ
- 1. What is Cyclavance?
Cyclavance is a 100mg/ml ciclosporin oral solution for cats and dogs with a 6 month shelf life once broached. Cyclavance allows accurate dosing to the nearest kg in one easy administration which limits the risks and inefficiencies of under and overdosing.
- 2. What can I use Cyclavance for?
Treatment of chronic manifestations of atopic dermatitis in dogs and, in cats, symptomatic treatment of chronic allergic dermatitis.
- 3. What is the on label dose rate?
In dogs = 5mg/kg & in Cats = 7mg/kg daily. Once clinical signs are improving the dosing frequency can be reduced to every other day or less frequently.
- 4. With or without food?
The product can be applied directly into the mouth or given with a small amount of food to ensure the whole dose is consumed.
- 5. How quickly will I see clinical results?
Usually clinical signs are improving between 4 to 8 weeks after the course has been started but may be sooner depending on concurrent medications and allergy control.
- 6. What are the common adverse effects and how are they managed?
It is common for the oily excipient to cause some gastrointestinal upsets such as vomiting and diarrhea. They are mild and transient and generally do not require the cessation of the treatment. Other side effects are listed on the datasheet and include symptoms like lethargy and inappetence. Reducing the dose or frequency of application can control these adverse effects.
- 7. Does CYCLAVANCE induce tumours?
While ciclosporin does not induce tumours, it does inhibit T-lymphocytes and therefore treatment with ciclosporin may lead to an increased incidence of clinically apparent malignancy due to the decrease in anti-tumour immune response. Lymphadenopathy observed on treatment with ciclosporin should be regularly monitored. There is thus a potentially increased risk of tumour progression if the tumour is already present before or occurs during the treatment with Cyclavance. This risk must be weighed against the clinical benefit.
- 8. Why has the Cyclavance gone all thick and lumpy?
A jelly-like formation may occur below 15°C which is however reversible at temperatures up to 25°C without affecting the quality of the product. After first opening, Cyclavance should be stored at room temperature between 15°C and 25°C.